文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

磺胺多辛-乙胺嘧啶对不良出生结局的剂量反应保护

Sulfadoxine-Pyrimethamine Exhibits Dose-Response Protection Against Adverse Birth Outcomes Related to Malaria and Sexually Transmitted and Reproductive Tract Infections.
PubMed 文献 · Clin Infect Dis · 2017-01-01

该前瞻性队列研究在赞比亚孕妇中评估间歇性预防治疗使用磺胺多辛-乙胺嘧啶(IPTp-SP)与不良出生结局的关联。结果显示,与0-1剂相比,≥2剂降低任何不良出生结局风险45%(OR 0.55),≥3剂进一步降低;对疟疾和淋球菌/沙眼衣原体感染孕妇保护更显著。

要点

  • IPTp-SP≥2剂较0-1剂降低任何不良出生结局风险45%(OR 0.55)。
  • ≥3剂较≥2剂进一步降低不良出生结局风险(OR 0.43)。
  • 对疟疾或淋球菌/衣原体感染孕妇,≥2剂保护作用更强。

核心结论

  • IPTp-SP对疟疾、性传播/生殖道感染及其他未明原因的不良出生结局具有保护作用。

研究设计与样本

  • 赞比亚前瞻性队列研究,孕妇接受IPTp-SP,比较0-1剂(n=126)与≥2剂(n=590)及≥2剂(n=310)与≥3剂(n=280)的不良出生结局比值比。

主要发现

  • ≥2剂较0-1剂降低任何不良出生结局风险45%(OR 0.55;95%CI 0.36,0.86),≥3剂进一步降低(OR 0.43;95%CI 0.27,0.68)。
  • ≥2剂较0-1剂降低早产风险58%(OR 0.42;95%CI 0.27,0.67),≥3剂进一步降低(OR 0.21;95%CI 0.13,0.35)。
  • 入组时有疟疾的孕妇≥2剂较0-1剂降低任何不良出生结局风险76%(OR 0.24;95%CI 0.09,0.66)。
  • 淋球菌和/或沙眼衣原体感染孕妇≥2剂较0-1剂降低任何不良出生结局风险92%(OR 0.08;95%CI 0.01,0.64)。
  • 无疟疾及STIs/RTIs的孕妇≥2剂较0-1剂降低不良出生结局风险73%(OR 0.27;95%CI 0.11,0.68)。

临床怎么用

  • 在疟疾流行区,对孕妇按指南推荐使用IPTp-SP并确保≥2剂可能减少不良出生结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a prospective cohort study in Zambia among pregnant women who received intermittent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP). METHODS: We calculated the odds ratios (ORs) of adverse birth outcomes by IPTp-SP exposure, 0-1 dose (n = 126) vs ≥2 doses (n = 590) and ≥2 doses (n = 310) vs ≥3 doses (n = 280) in 7 categories of malaria infection and sexually transmitted and reproductive tract infections (STIs/RTIs). RESULTS: We found no significant differences in baseline prevalence of infection across IPTp-SP exposure groups. However, among women given 2 doses compared to 0-1 dose, the odds of any adverse birth outcome were reduced 45% (OR, 0.55; 95% confidence interval [CI], 0.36, 0.86) and 13% further with ≥3 doses (OR, 0.43; 95% CI, 0.27, 0.68). Two or more doses compared to 0-1 dose reduced preterm delivery by 58% (OR, 0.42; 95% CI, 0.27, 0.67) and 21% further with ≥3 doses (OR, 0.21; 95% CI, 0.13, 0.35). Women with malaria at enrollment who received ≥2 doses vs 0-1 had 76% lower odds of any adverse birth outcome (OR, 0.24; 95% 0.09, 0.66), and Neisseria gonorrhoeae and/or Chlamydia trachomatis had 92% lower odds of any adverse birth outcome (OR, 0.08; 95% CI, 0.01, 0.64). Women with neither a malaria infection nor STIs/RTIs who received ≥2 doses had 73% fewer adverse birth outcomes (OR, 0.27; 95% CI, 0.11, 0.68). CONCLUSIONS: IPTp-SP appears to protect against malaria, STIs/RTIs, and other unspecified causes of adverse birth outcome.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chico RM, Chaponda EB, Ariti C, et al. Sulfadoxine-Pyrimethamine Exhibits Dose-Response Protection Against Adverse Birth Outcomes Related to Malaria and Sexually Transmitted and Reproductive Tract Infections. Clin Infect Dis. 2017. PMID: 28329383. doi:10.1093/cid/cix026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。